Evidence map›Paper›PMID 30190895›Full record

ArticleMelanoma management2016

Vaccine therapy + dasatinib for the treatment of patients with stage IIIB-IV melanoma.

Ahmad A Tarhini, Hussein Tawbi, Walter J Storkus

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Melanoma management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Ahmad A TarhiniDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Hussein TawbiDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Walter J StorkusMelanoma Program of the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
The University of Texas MD Anderson Cancer Center · USUniversity of Pittsburgh · USUPMC Hillman Cancer Center · US

Funding

Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
Combinational Immunotherapy Targeting the Melanoma-Associated VasculatureR01CA169118 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI STORKUS, WALTER J. · 2012 to 2016
$2.1M
NCI NIH HHS P50 CA121973NCI NIH HHS R01 CA169118
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvantdasatinibdendritic cellsimmunotherapymelanomaT-cells receptortumor microenvironmenttyrosine kinase inhibitorsvaccine

Identifiers

PMID30190895
PMCPMC6094598
OpenAlexW2559551051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.